Ranibizumab Fails to Beat Saline in Avoiding VitrectomyRanibizumab Fails to Beat Saline in Avoiding Vitrectomy
Patients with vitreous hemorrhage from proliferative diabetic retinopathy who received intravitreal injections of ranibizumab or saline had about the same rates of vitrectomy by 16 weeks. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 1, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
NETAG issues appraisal and recommendation on aflibercept for AMD
Source: NETAG
Area: Evidence > Drug Specific Reviews
The NHS North East Treatment Advisory Group (NETAG) has undertaken an appraisal of aflibercept (Eylea®) within its licensed indication for the management of neovascular (wet) age-related macular degeneration (AMD). The Group recommends its use, within its licensed indication, for the treatment of newly diagnosed and untreated wet AMD. It does not however recommend its use for the same episode of AMD refractory to treatment with other biological therapies such as ranibizumab. This recommendation is contingent on a maximum cost per aflibercept dose as stated in the ...
Source: NeLM - Drug Specific Reviews - January 21, 2013 Category: Drugs & Pharmacology Source Type: news
NICE makes u-turn decision on Lucentis
A UK health watchdog has recommended the use of Lucentis for the treatment of visual impairment caused by diabetic macular oedema (DMO) after manufacturer Novartis dropped the price of the drug. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 7, 2013 Category: Pharmaceuticals Source Type: news
NICE to back use of Lucentis for eye condition
Thousands of people with a devastating eye condition could be offered a potentially sight-saving treatment following a U-turn by the health watchdog. (Source: HSJ)
Source: HSJ - January 4, 2013 Category: UK Health Source Type: news
AUDIO: Eye treatment Lucentis for diabetics
Patients whose eyesight is badly affected by diabetes are going to be allowed to use the drug Lucentis throughout the UK. Professor Yit Yang, an ophthalmologist at the Royal Wolverhampton Hospital explains how the drug works. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - January 4, 2013 Category: Consumer Health News Source Type: news
UK backs Lucentis for new use after Novartis cuts price
LONDON (Reuters) - Britain's healthcare cost watchdog has given its backing to eye drug Lucentis to treat diabetes-related problems after Swiss drugmaker Novartis offered it at a discount to the National Health Service. (Source: Reuters: Health)
Source: Reuters: Health - January 4, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
HSJ live: rolling news 4.1.2013
NICE approves Lucentis and the rest of today’s news (Source: HSJ)
Source: HSJ - January 4, 2013 Category: UK Health Source Type: news
NICE final draft guidance supports use of ranibizumab for diabetic macular oedema
Source: NICE
Area: News
In its Final Appraisal Determination, NICE is supporting the use of ranibizumab as an option for treating visual impairment caused by diabetic macular oedema (DMO). NICE conducted a rapid review of the original guidance, published in November 2011, because the manufacturer submitted a revised Patient Access Scheme, together with updated analyses showing the drug's superior relative effect among a sub-group of people with DMO.
The draft guidance states that ranibizumab is now recommended as an option for treating visual impairment due to diabetic macular oedema if the eye has a central re...
Source: NeLM - News - January 4, 2013 Category: Drugs & Pharmacology Source Type: news
UK backs ranibizumab (Lucentis) for new use after Novartis cuts price
LONDON (Reuters) - Britain's healthcare cost watchdog has given its backing to ranibizumab (Lucentis)
to treat diabetic macular edema after Swiss drugmaker Novartis offered it at a discount to the National Health
Service. (Source: Modern Medicine)
Source: Modern Medicine - January 4, 2013 Category: Journals (General) Source Type: news
Sight-saving drug for diabetics approved for NHS use
Thousands of patients stand to benefit from a u-turn on guidance to approve a treatment that could save their sight. (Source: Telegraph Health)
Source: Telegraph Health - January 3, 2013 Category: Consumer Health News Tags: SIGHT LUCENTIS BLIND NICE DMO Source Type: news
Avastin and Lucentis are equivalent in treating age-related macular degeneration
At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD), improve vision when administered monthly or on an as needed basis, although greater improvements in vision were seen with monthly administration for this common, debilitating eye disease, according to researchers supported by the National Institutes of Health. (Source: News from NEI)
Source: News from NEI - April 30, 2012 Category: Opthalmology Tags: News and Events Source Type: news
The use of unlicenced treatment for wet AMD
Reacting to news the Novartis is challenging the use of Avastin as an alternative to Lucentis for wet Age related Macular Degeneration Neal Patel, RPS spokesperson said:
“Putting patients at the heart of decisions around therapy choice is what should drive NHS organisations and clin (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - April 23, 2012 Category: Drugs & Pharmacology Source Type: news
Position of the MPA regarding Lucentis and Avastin
Lucentis (ranibizumab) is approved for the treatment of neovascular age related macular degeneration (AMD), for the treatment of visual impairment due to diabetic macular oedema (DME) and retinal vein occlusions (RVO). (Source: MPA RSS news -)
Source: MPA RSS news - - March 16, 2012 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news
